سعر ازي ونس 200مجم/5مل معلق 30 مل 2024

Azi-Once: azithromycin 200 mg/5 ml oral suspension, 30 ml bottle (1200 mg azithromycin in total); macrolide (azalide) antibacterial. Company: Jamjoom Pharmaceuticals.

• Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniaePopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniaePopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions: diarrhea (5 to 14%), nausea (3 to 18%), abdominal pain (3 to 7%) or vomiting (2 to 7%). With adult multiple-dose regimens the most frequent were diarrhea/loose stools (4 to 5%), nausea (3%) and abdominal pain (2 to 3%), with no other reaction above 1%; single 1-2 g doses produce more gastrointestinal effects. Postmarketing reports include hearing loss/tinnitus, hepatic failure, pancreatitis, interstitial nephritis, arrhythmias including torsades de pointes, and severe skin reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious hypersensitivity reactions, including angioedema and anaphylaxis, and severe cutaneous reactions (AGEP, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS) have been reported, rarely fatal; allergic symptoms may recur after symptomatic therapy is stopped. Discontinue if an allergic reaction occurs and institute appropriate therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatotoxicity: abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis and hepatic failure (some fatal) have been reported. Discontinue immediately if signs and symptoms of hepatitis occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation and torsades de pointes have been reported. Consider the risk in patients with known QT prolongation or history of torsades, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure, patients on drugs known to prolong the QT interval, patients with uncorrected hypokalemia or hypomagnesemia or clinically significant bradycardia, and patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmics. Elderly patients may be more susceptible.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• NelfinavirCo-administration increased azithromycin serum concentrations; dose adjustment not recommended, but monitor closely for known azithromycin adverse reactions such as liver enzyme abnormalities and hearing impairment.DailyMed (U.S. National Library of Medicine)
• Warfarin (oral anticoagulants)Spontaneous postmarketing reports suggest concomitant azithromycin may potentiate the effects of oral anticoagulants; monitor prothrombin times carefully.DailyMed (U.S. National Library of Medicine)
• Digoxin and colchicine (P-glycoprotein substrates)Concomitant use of macrolides, including azithromycin, with P-gp substrates such as digoxin and colchicine has resulted in increased serum levels of the P-gp substrate; clinical and, where possible, serum digoxin monitoring is needed.DailyMed (U.S. National Library of Medicine)

• Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. Developmental toxicity studies in rats, mice and rabbits showed no drug-induced fetal malformations at doses up to 4, 2 and 2 times the adult human daily dose of 500 mg (body surface area).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Azithromycin is present in human milk; non-serious adverse reactions have been reported in breastfed infants after maternal administration. No data on effects on milk production. Advise women to monitor the breastfed infant for diarrhea, vomiting or rash.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Azithromycin: Macrolide antibacterial that binds the 23S rRNA of the bacterial 50S ribosomal subunit and inhibits bacterial protein synthesis.